UBS/CALL/ELI LILLY & CO/650/0.1/20.12.24 | Market Closed - Deutsche Boerse AG 18:38:33 14/06/2024 BST | ||
| 24.27 EUR | +2.19% |
|
| Current month | +29.99% | ||
| 1 month | +66.92% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 24.27 | +2.19% |
| 13/06/24 | 23.75 | +3.71% |
| 12/06/24 | 22.9 | -8.33% |
| 11/06/24 | 24.98 | +11.57% |
| 10/06/24 | 22.39 | +2.14% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 06:38 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| WKN | UL7760 |
| ISIN | CH1294696575 |
| Date issued | 07/09/2023 |
| Strike | 650 $ |
| Maturity | 20/12/2024 (187 Days) |
| Parity | 10 : 1 |
| Emission price | 4.53 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 25.48 € |
|---|---|
| Lowest since issue | 3.56 € |
| Spread | 0.05 € |
| Spread % | 0.21% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
878.4
USD
Average target price
855.4
USD
Spread / Average Target
-2.63%
- Stock Market
- Warrants
- Warrant